CGEM
Cullinan TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
CGEM has an unusually dense 2026 catalyst slate for its size: CLN-978 autoimmune data in multiple indications, CLN-049 AML updates, and zipalertinib regulatory/Phase 3 progress, all backed by runway into 2029.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.5.
What can break
CLN-049 could struggle to produce a durable AML signal or acceptable tolerability as Cullinan pushes toward registrational development.
Momentum
84
Value
41
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $26.00 · Bear $9.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $30.58
Why
Momentum84 · Δ7d +2.5
Value41 · Δ7d +0.0
Sentiment66 · Δ7d +1.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
84
34% active weight
Current posture
7d trendFlat
Δ7d
+2.5
Δ21d
-1.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+13.2
Why this grade
Composite grade A. Momentum 83.5 / Value 41.1 / Sentiment 66.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$942.77M
Beta
-0.09
Shares Out
59.08M
P/E (TTM) · Derived
-5.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.39
Rev YoY
-
EPS YoY
-23.2%
Gross Margin
-
Op Margin
-
Net Debt
-$398.98M
Current Ratio
10.45
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology